Profile data is unavailable for this security.
About the company
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.
- Revenue in USD (TTM)84.04m
- Net income in USD-30.59m
- Incorporated2008
- Employees100.00
- LocationG1 Therapeutics Inc700 Park Offices Drive, Suite 200RESEARCH TRIANGLE PARK 27709United StatesUSA
- Phone+1 (919) 213-9835
- Fax+1 (919) 741-5830
- Websitehttps://www.g1therapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merrimack Pharmaceuticals Inc | 0.00 | -1.18m | 217.98m | -- | -- | 11.48 | -- | -- | -0.0826 | -0.0826 | 0.00 | 1.31 | 0.00 | -- | -- | -- | -6.05 | -23.52 | -6.22 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 221.49m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0149 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| AVITA Medical Inc | 50.14m | -35.38m | 225.75m | 207.00 | -- | 4.58 | -- | 4.50 | -1.40 | -1.40 | 1.98 | 1.91 | 0.4778 | 1.96 | 8.48 | 242,236.70 | -33.71 | -- | -38.04 | -- | 84.93 | -- | -70.56 | -- | 7.46 | -35.33 | 0.448 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| INmune Bio Inc | 155.00k | -30.01m | 228.63m | 11.00 | -- | 5.45 | -- | 1,475.06 | -1.67 | -1.67 | 0.0086 | 2.12 | 0.0022 | -- | 0.0284 | 14,090.91 | -43.24 | -37.82 | -54.85 | -41.86 | -- | -- | -19,360.00 | -14,901.03 | -- | -13.06 | 0.2064 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -42.49m | 233.90m | 32.00 | -- | 1.46 | -- | -- | -0.3343 | -0.3343 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -23.84 | -41.75 | -25.56 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Puma Biotechnology Inc | 235.64m | 21.59m | 234.44m | 185.00 | 10.76 | 4.33 | 7.08 | 0.9949 | 0.4515 | 0.4515 | 4.96 | 1.12 | 1.04 | 10.80 | 5.23 | 1,273,714.00 | 9.54 | -12.21 | 15.66 | -20.53 | 73.40 | 78.78 | 9.16 | -11.79 | 1.50 | 3.10 | 0.6509 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 234.74m | 100.00 | -- | 8.45 | -- | 2.79 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Metagenomi Inc | 44.76m | -68.26m | 236.83m | 236.00 | -- | -- | -- | 5.29 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| AC Immune SA | 16.35m | -59.90m | 237.08m | 133.00 | -- | 1.34 | -- | 14.50 | -0.7089 | -0.7089 | 0.1925 | 1.79 | 0.0803 | -- | 1.92 | 122,913.30 | -29.41 | -18.25 | -31.56 | -19.52 | -- | -- | -366.41 | -148.29 | -- | -89.52 | 0.0213 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Veru Inc | 15.93m | -64.59m | 238.60m | 189.00 | -- | 4.62 | -- | 14.98 | -0.758 | -0.758 | 0.177 | 0.3525 | 0.1728 | 1.01 | 5.10 | 84,285.19 | -70.07 | -42.91 | -101.20 | -54.41 | 50.31 | 72.41 | -405.44 | -104.96 | 2.79 | -- | 0.1584 | -- | -58.59 | 0.5394 | -10.84 | -- | 67.39 | -- |
| 2Seventy Bio Inc | 100.39m | -217.57m | 244.69m | 274.00 | -- | 0.944 | -- | 2.44 | -4.41 | -4.41 | 2.04 | 5.04 | 0.1643 | -- | 5.84 | 366,375.90 | -35.61 | -- | -40.20 | -- | 83.15 | 91.76 | -216.73 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Lyra Therapeutics Inc | 1.56m | -62.68m | 245.69m | 88.00 | -- | 2.58 | -- | 157.69 | -1.32 | -1.32 | 0.0313 | 1.56 | 0.0123 | -- | -- | 17,704.54 | -49.63 | -58.01 | -57.37 | -68.69 | -- | -- | -4,023.11 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -37.54m | 247.16m | 10.00 | -- | 2.06 | -- | -- | -0.6375 | -0.6375 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -22.78 | -36.79 | -25.71 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1123 | -- | -- | -- | 39.47 | -- | -- | -- |
| Fennec Pharmaceuticals Inc | 21.25m | -16.05m | 250.13m | 36.00 | -- | -- | -- | 11.77 | -0.6042 | -0.6042 | 0.7994 | -0.43 | 0.79 | 0.9217 | 4.10 | -- | -59.64 | -73.43 | -77.06 | -84.32 | 94.08 | -- | -75.50 | -383.28 | 3.27 | -3.90 | 1.63 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Century Therapeutics Inc | 2.24m | -136.67m | 251.03m | 152.00 | -- | 0.9895 | -- | 112.32 | -2.30 | -2.30 | 0.0377 | 3.06 | 0.0053 | -- | -- | 14,703.95 | -32.26 | -- | -34.19 | -- | -- | -- | -6,115.12 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to G1 Therapeutics Inc's reporting currency: US Dollar USD
15.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.97m | 3.77% |
| Susquehanna Financial Group LLLPas of 31 Dec 2023 | 1.58m | 3.02% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Mar 2024 | 802.84k | 1.54% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 660.95k | 1.27% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 630.40k | 1.21% |
| Group One Trading LPas of 31 Dec 2023 | 521.33k | 1.00% |
| D. E. Shaw & Co. LPas of 31 Dec 2023 | 495.45k | 0.95% |
| Geode Capital Management LLCas of 31 Dec 2023 | 460.78k | 0.88% |
| abrdn, Inc.as of 31 Dec 2023 | 423.87k | 0.81% |
| Marshall Wace LLPas of 31 Dec 2023 | 360.29k | 0.69% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
